Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001520 · ClinicalTrials.gov registry record · Phase 2
Neural Substrates in Nicotine Withdrawal
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 218
- Enrollment target
NCT01001520: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT01001520 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 218 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01001520, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 218 participants
- Enrollment target
Study Summary
This study will test the hypothesis that a medication called tolcapone (Brand Name: Tasmar) will help reduce cognitive problems that smokers experience when they quit. This study will also determine whether the benefits of this medication differ depending on a smokers' genetic background.
Interventions
- DRUG Placebo
- DRUG Tolcapone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01001520
The ClinicalTrials.gov registry entry for NCT01001520 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01001520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01001520 about?
NCT01001520 is a clinical study titled "Neural Substrates in Nicotine Withdrawal". This study will test the hypothesis that a medication called tolcapone (Brand Name: Tasmar) will help reduce cognitive problems that smokers experience when they quit. This study will also determine whether the benefits of this medication differ depending on a smokers' genetic background.
What is the current status of trial NCT01001520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 218 participants. The study started on 2010-01. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01001520?
The interventions under investigation include: Placebo (DRUG), Tolcapone (DRUG).
Who is sponsoring clinical trial NCT01001520?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.